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Davydenko O.N., Myronyk O.V., Sydorchuk A.S. 
CLINICAL EFFICACY OF THE DRUG "GEPADIF" IN COMPLEX 
TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C 
Bukovinian State Medical University 
Chernivtsi, Teatral’na Sq., 2, 58000 
КЛІНІЧНА ЕФЕКТИВНІСТЬ ЗАСТОСУВАННЯ ПРЕПАРАТУ 
„ГЕПАДИФ” В КОМПЛЕКСНОМУ ЛІКУВАННІ ХВОРИХ НА 
ХРОНІЧНИЙ ГЕПАТИТ С 
 
Abstract. In this paper we describe the clinical efficacy of “Hepadif”in holiatry 
of patients with chronic viral hepatitis C. 
Key words: chronic hepatitis C, treatment, clinical effectiveness, 
alaninaminotransferase (ALAT) level. 
Анотація. В роботі доведена ефективність препарату «Гепадиф» 
вкомплексному лікуванні хворих на хронічий гепатит С. 
Ключові слова. Хронічний гепатит С, лікування, клінічна ефективність, 
аланін амінотрансфераза. 
Introduction.  
Actually relevant and unresolved problem is the treatment of chronic viral 
hepatitis. In Ukraine the incidence of chronic hepatitis has increased in 2 times [3, 4]. 
According to WHO, about 1% of world population are infected with hepatitis C virus 
[1, 2].  
Chronic hepatitis C occur in varying degrees, accompanied with violations of 
metabolic processes [5]. The disruption of protein synthesis leads to changes in the 
amino acid composition of the blood, disorders of the processes of neutralization of 
ammonia and coagulation. Inflammatory and necrotic processes in the liver 
accompanied by impairment of lipid peroxidation, decreased antioxidant resources, 
resulting in damaged membrane of hepatocyte [8]. All this necessitates the inclusion 
of medications in the comprehensive treatment of patients with chronic hepatitis C. 
One such remedy is the "Hepadif". This combination drug, which is caused by 
complex influence of the components included in its composition. Stimulates the 
metabolism of fat components of the β-oxidative transformation of free fatty acids in 
the mitochondria of hepatocytes, biosynthetic processes, prevents necrosis of 
hepatocytes, normalize the process of proliferation of hepatocytes, the liver enzyme 
system and restores normal liver function [6].  
The presence of adenosine, which is a component of coenzymes, nucleic acids, 
provides the regulation of hematopoiesis. B vitamins (cyanocobalamin, riboflavin, 
pyridoxine) regulate the redox processes involved in protein, fat and carbohydrate 
metabolism, in the metabolism of tryptophan, methionine, cysteine, glutamic acid and 
other amino acids. Pyridoxine promotes the normalization of lipid metabolism. 
Cyanocobalamin is involved in the process transmetilirovania, hydrogen transfer, the 
formation of methionine, nucleic acids, choline, creatine. Carnitine promotes the 
breakdown of long-chain fatty acids and the substitution of fatty acid metabolic shunt 
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of carbohydrate, improves digestion. Antitoxic fraction liver extract antitoxic is the 
purified extract of the liver and has anti-toxic effect [7].  
Main text.  
The purpose of the study. To study the clinical efficiency "Hepadif" in 
complex treatment of patients with chronic hepatitis C. 
Materials and methods. The investigation included 43 patients with chronic 
hepatitis C, moderate severity course of 25-55 years. Males was 18, female – 25. 
Single-blind method, all patients randomized into two groups. Patients received basic 
therapy. Patients of the main group received “Hepadif” intravenously at the rate of 
8,625 mg/kg body mass – contents of 1 vial of the drug is dissolved in 400-500 ml of 
5% glucose solution for 5 days followed by administration of 2 capsules 2 times a 
day, regardless of meals during the month. Patients in the control group received 
Essencialle® Forte N 2 capsules 3 times a day. All patients underwent complex 
clinical and laboratory examination and estimation of the functional state of the liver. 
The data were analyzed statistically: the arithmetic mean was calculated and its 
error. The average difference between study groups was assessed using unpaired 
bilateral Student test.  
The results of the study and their discussion. Under the influence of complex 
treatment with use of the drug "Hepadif" noted positive dynamics of clinical 
symptoms. So, on the 11th day of treatment complaints of general weakness showed 
31.5% of patients of the main group, decrease in appetite in 32%, nausea – 15,8%, a 
feeling of heaviness in the epigastrium and right hypochondrium is 24.2%. 
At the end of treatment nausea and a feeling of heaviness had not said no 
patient, while 12.3% of patients in the control group, these symptoms persisted.  
Under the influence of treatment significantly improved indicators of total 
bilirubin in both groups (table. 1). 
Table 1.  
Dynamics of biochemical parameters of blood in patients 
in chronic hepatitis C (М±m) 
Parameter Basic group Control group 
Before 
treatment 
After treatment Before 
treatment 
After treatment 
Bilirubinum, 
mkmol/l 
34,2±1,8 17,8±1,6* 31,7±1,9 19,6±1,8* 
ALAT, 
mmol/(l/hour) 
1,2±0,3 0,64±0,13* 1,08±0,3 0,75±0,12 
Alkaline 
phosphatase, IU 
298,6±12,4 175,8±11,6* 302,3±12,7 338,5±12,1*  
** 
Tymol test, UA 6,4±0,8 5,3±0,6 6,3±0,7 5,4±0,6 
Albuminum, g/l 51,7±4,2 52,3±4,2 53,4±4,4 54,1±4,2 
 
Note: *- Р≤0,05 in patients before and after treatment 
 ** - Р≤0,05 after treatment in basic and control groups  
  
 
ISSN 2227-6920                                                                                     Medicine, veterinary medicine and pharmaceuticals 4 
SWorld Journal                                                                                                                                 Issue 11.Vol.6 
Summary and Conclusions.  
We were considered the inclusion of “Hepadif” into holiatry of chronic hepatitis 
C independently of gender. Dynamics of activity of ALAT and alkaline phosphatase 
were significantly positive in patients receiving "Hepadif". It should be noted that the 
normalization of biochemical parameters was faster in the main group of patients. As 
for the indicators of cholestasis, patients of the control group dynamics of alkaline 
phosphatase was significantly negative.  
Thus, the present study demonstrated that the use of the drug "Hepadif" likely 
contributes to the improvement of biochemical parameters of blood, reduction of 
pathological processes in the liver, a more rapid regression of clinical symptoms. 
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